Enclomiphene is the trans-isomer of clomiphene citrate, isolated to provide the testosterone-stimulating effects without the estrogenic side effects associated with the zuclomiphene isomer found in standard Clomid. It works by blocking estrogen receptors in the hypothalamus and pituitary, which removes negative feedback and increases GnRH, LH, and FSH secretion.
The result is increased natural testosterone production. Unlike exogenous testosterone, enclomiphene stimulates the HPT axis rather than suppressing it. LH and FSH rise, the testes produce more testosterone, and spermatogenesis is maintained or enhanced. This makes it an attractive option for men with secondary hypogonadism who want to preserve fertility.
Typical dosing ranges from 12.5-25 mg daily, taken orally. Most men see total testosterone increases of 200-400 ng/dL within 4-8 weeks. The response depends on baseline testicular function: men with primary hypogonadism (damaged or absent testicular tissue) will not respond meaningfully, as the testes cannot increase production regardless of LH stimulation.
Enclomiphene is not FDA-approved as a standalone product in the US, but it is available through compounding pharmacies. Clinical trials showed it effectively raised testosterone in hypogonadal men with fewer side effects than traditional clomiphene. It's increasingly used as a first-line treatment for younger men and as an alternative to TRT for those who want to avoid injections.